Company intelligence / Profile preview

StemSight

Ownership: Private
Development stage: Preclinical

Overview

StemSight develops off-the-shelf regenerative cell therapies using iPSC-derived limbal stem cells and biomaterial scaffolds to treat severe forms of corneal blindness such as LSCD. The company has raised €2.3 million in early funding to advance preclinical studies, expand R&D, pilot manufacturing, and prepare for first-in-human clinical trials. No published human efficacy data yet; preclinical progress reported.

Therapeutic areas: Ophthalmology
Modalities: Induced pluripotent stem cells (iPSCs)Cell therapyBiomaterials (as delivery/support technology)
Industry: Biotech

Drug pipeline

1 asset

STE-101

Preclinical

Partnerships

Participating in the €8M EU-funded KeratOPrinter Project; no major pharma partnerships disclosed as of May 2025.

Beyond the preview

Go deeper on StemSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemSight.

Explore the full profile